Literature DB >> 19175313

DNA mismatch binding and antiproliferative activity of rhodium metalloinsertors.

Russell J Ernst1, Hang Song, Jacqueline K Barton.   

Abstract

Deficiencies in mismatch repair (MMR) are associated with carcinogenesis. Rhodium metalloinsertors bind to DNA base mismatches with high specificity and inhibit cellular proliferation preferentially in MMR-deficient cells versus MMR-proficient cells. A family of chrysenequinone diimine complexes of rhodium with varying ancillary ligands that serve as DNA metalloinsertors has been synthesized, and both DNA mismatch binding affinities and antiproliferative activities against the human colorectal carcinoma cell lines HCT116N and HCT116O, an isogenic model system for MMR deficiency, have been determined. DNA photocleavage experiments reveal that all complexes bind to the mismatch sites with high specificities; DNA binding affinities to oligonucleotides containing single base CA and CC mismatches, obtained through photocleavage titration or competition, vary from 10(4) to 10(8) M(-1) for the series of complexes. Significantly, binding affinities are found to be inversely related to ancillary ligand size and directly related to differential inhibition of the HCT116 cell lines. The observed trend in binding affinity is consistent with the metalloinsertion mode where the complex binds from the minor groove with ejection of mismatched base pairs. The correlation between binding affinity and targeting of the MMR-deficient cell line suggests that rhodium metalloinsertors exert their selective biological effects on MMR-deficient cells through mismatch binding in vivo.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19175313      PMCID: PMC2747594          DOI: 10.1021/ja8081044

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  38 in total

Review 1.  Frameshift mutation, microsatellites and mismatch repair.

Authors:  B S Strauss
Journal:  Mutat Res       Date:  1999-11       Impact factor: 2.433

2.  Structure of a photoactive rhodium complex intercalated into DNA.

Authors:  C L Kielkopf; K E Erkkila; B P Hudson; J K Barton; D C Rees
Journal:  Nat Struct Biol       Date:  2000-02

3.  Recognition of base mismatches in DNA by 5,6-chrysenequinone diimine complexes of rhodium(III): a proposed mechanism for preferential binding in destabilized regions of the double helix.

Authors:  B A Jackson; J K Barton
Journal:  Biochemistry       Date:  2000-05-23       Impact factor: 3.162

4.  Competency in mismatch repair prohibits clonal expansion of cancer cells treated with N-methyl-N'-nitro-N-nitrosoguanidine.

Authors:  J M Carethers; M T Hawn; D P Chauhan; M C Luce; G Marra; M Koi; C R Boland
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

5.  The role of DNA mismatch repair in platinum drug resistance.

Authors:  D Fink; S Nebel; S Aebi; H Zheng; B Cenni; A Nehmé; R D Christen; S B Howell
Journal:  Cancer Res       Date:  1996-11-01       Impact factor: 12.701

Review 6.  A mutator phenotype in cancer.

Authors:  L A Loeb
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

7.  Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation.

Authors:  M Koi; A Umar; D P Chauhan; S P Cherian; J M Carethers; T A Kunkel; C R Boland
Journal:  Cancer Res       Date:  1994-08-15       Impact factor: 12.701

Review 8.  Delocalized lipophilic cations selectively target the mitochondria of carcinoma cells.

Authors:  J S Modica-Napolitano; J R Aprille
Journal:  Adv Drug Deliv Rev       Date:  2001-07-02       Impact factor: 15.470

Review 9.  Deficient DNA mismatch repair: a common etiologic factor for colon cancer.

Authors:  P Peltomäki
Journal:  Hum Mol Genet       Date:  2001-04       Impact factor: 6.150

Review 10.  Drug delivery to mitochondria: the key to mitochondrial medicine.

Authors:  M P Murphy; R A Smith
Journal:  Adv Drug Deliv Rev       Date:  2000-03-30       Impact factor: 15.470

View more
  22 in total

1.  Using metal complex reduced states to monitor the oxidation of DNA.

Authors:  Eric D Olmon; Michael G Hill; Jacqueline K Barton
Journal:  Inorg Chem       Date:  2011-11-01       Impact factor: 5.165

2.  Targeting a ruthenium complex to the nucleus with short peptides.

Authors:  Cindy A Puckett; Jacqueline K Barton
Journal:  Bioorg Med Chem       Date:  2010-04-08       Impact factor: 3.641

3.  Biological effects of simple changes in functionality on rhodium metalloinsertors.

Authors:  Alyson G Weidmann; Alexis C Komor; Jacqueline K Barton
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2013-06-17       Impact factor: 4.226

4.  A Family of Rhodium Complexes with Selective Toxicity toward Mismatch Repair-Deficient Cancers.

Authors:  Kelsey M Boyle; Jacqueline K Barton
Journal:  J Am Chem Soc       Date:  2018-04-17       Impact factor: 15.419

5.  Targeted Chemotherapy with Metal Complexes.

Authors:  Alyson G Weidmann; Alexis C Komor; Jacqueline K Barton
Journal:  Comments Mod Chem A Comments Inorg Chem       Date:  2014-05       Impact factor: 4.533

6.  Rhodium metalloinsertor binding generates a lesion with selective cytotoxicity for mismatch repair-deficient cells.

Authors:  Julie M Bailis; Alyson G Weidmann; Natalie F Mariano; Jacqueline K Barton
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-20       Impact factor: 11.205

7.  Targeting DNA Mismatches with Rhodium Metalloinsertors.

Authors:  Kelsey M Boyle; Jacqueline K Barton
Journal:  Inorganica Chim Acta       Date:  2016-01-16       Impact factor: 2.545

8.  A monofunctional platinum complex coordinated to a rhodium metalloinsertor selectively binds mismatched DNA in the minor groove.

Authors:  Alyson G Weidmann; Jacqueline K Barton
Journal:  Inorg Chem       Date:  2015-09-23       Impact factor: 5.165

Review 9.  The path for metal complexes to a DNA target.

Authors:  Alexis C Komor; Jacqueline K Barton
Journal:  Chem Commun (Camb)       Date:  2013-05-07       Impact factor: 6.222

Review 10.  Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs.

Authors:  Sabine H van Rijt; Peter J Sadler
Journal:  Drug Discov Today       Date:  2009-09-24       Impact factor: 7.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.